Preventing and managing aberrant drug-related behavior in primary care: Systematic review of outcomes evidence

Charles E. Argoff, MD; Meldon Kahan, MD; Edward M. Sellers, MD

doi:10.5055/jom.2014.0201

Authors

Charles E. Argoff, MD
Meldon Kahan, MD
Edward M. Sellers, MD

DOI:

https://doi.org/10.5055/jom.2014.0201

Keywords:

opioids, drug abuse, abuse-deterrence, abuse liability, pain management

Abstract

Several strategies for preventing, identifying, and responding to aberrant opioid-related behaviors are recommended in pain management guidelines. This systematic review evaluated data supporting basic strategies for addressing aberrant opioid- related behaviors. Risk reduction strategies were identified via a review of available guidelines. Systematic literature searches of PubMed (May 1, 2007- January 18, 2013) identified articles with evidence relevant to nine basic strategies. Reference lists from relevant articles were reviewed for additional references of interest. Levels of evidence for articles identified were graded on a four-point scale (strongest evidence = level 1; weakest evidence = level 4) using Oxford Centre for Evidence-Based Medicine Levels of Evidence criteria. Weak to moderate evidence supports the value of thorough patient assessment, risk-screening tools, controlled substance agreements, careful dose titration, opioid dose ceilings, compliance monitoring, and adherence to practice guidelines. Moderate to strong evidence suggests that prescribing tamper-resistant opioids may help prevent misuse but may also have the unintended consequence of prompting a migration of users to other marketed opioids, heroin, or other substances. Similarly, preliminary evidence suggests that although recent regulatory and legal efforts may reduce misuse, they also impose barriers to the legitimate treatment of pain. Despite an absence of consistent, strong supporting evidence, clinicians are advised to use each of the available risk-mitigation strategies in combination in an attempt to minimize the risk of abuse in opioid treatment patients. Physicians must critically evaluate their opioid prescribing and not only increase their efforts to prevent substance

Author Biographies

Charles E. Argoff, MD

Professor of Neurology, Albany Medical College, Albany, New York

Meldon Kahan, MD

Associate Professor, Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada

Edward M. Sellers, MD

President and Principal, DL Global Partners, Toronto, Ontario, Canada

References

Results from the 2008 National Survey on Drug Use and Health: National Findings. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Available at http://www.samhsa.gov/data/NSDUH/2K8NSDUH/tabs/Sect1peTabs1to46.htm#Tab1.1B. Accessed November 21, 2013.

Spitz A, Moore AA, Papaleontiou M, et al.: Primary care providers’ perspective on prescribing opioids to older adults with chronic non-cancer pain: A qualitative study. BMC Geriatr. 2011; 11: 35.

Manchikanti L, Manchukonda R, Damron KS, et al.: Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006; 9(1): 57-60.

Bhamb B, Brown D, Hariharan J, et al.: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006; 22(9): 1859-1865.

Reisfield GM, Webb FJ, Bertholf RL, et al.: Family physicians’ proficiency in urine drug test interpretation. J Opioid Manag. 2007; 3(6): 333-337.

Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. National Opioid Use Guideline Group (NOUGG). Available at http://nationalpaincentre.mcmaster.ca/opioid/. Accessed November 21, 2013.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I - Evidence assessment. Pain Physician. 2012; 15(3 suppl): S1-S66.

Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - Guidance. Pain Physician. 2012; 15(3 suppl): S67-S116.

Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). United States Food and Drug Administration. Available at http://www.er-la-opioidrems.com/. Accessed November 21, 2013.

Washington State Agency Medical Directors' Group: Interagency guidelines on opioid dosing for chronic non-cancer pain: An educational aid to improve care and safety with opioid therapy. Available at http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Accessed November 21, 2013.

Laws of Florida Chapter 2011-141. Florida State Legislature. Available at http://laws.flrules.org/files/Ch_2011-141.pdf. Accessed November 21, 2013.

Oxford Centre for Evidence-Based Medicine - Levels of Evidence: Oxford University. Available at http://www.cebm.net/index.aspx?o=1025. Accessed November 20, 2013.

Kahan M, Srivastava A, Wilson L, et al.: Misuse of and dependence on opioids: Study of chronic pain patients. Can Fam Physician. 2006; 52(9): 1081-1087.

Brown J, Setnik B, Lee K, et al.: Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011; 7(6): 467-483.

Jamison RN, Serraillier J, Michna E: Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res Treat. 2011; 2011: 941808.

Kahan M, Wilson L, Mailis-Gagnon A, et al.: Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations. Can Fam Physician. 2011; 57(11): 1269-1276.

Larance B, Degenhardt L, Lintzeris N, et al.: Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011; 30(3): 236-245.

United States Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Results from the 2010 National Survey on Drug Use and Health: National Findings. Available at http://www.oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf. Accessed November 21, 2013.

Joranson DE, Gilson AM: Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. 2005; 30(4): 299-301.

Morasco BJ, Dobscha SK: Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry. 2008; 30(2): 93-99.

Green TC, Grimes Serrano JM, Licari A, et al.: Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend. 2009; 103(1-2): 65-73.

Hartzler B, Donovan DM, Huang Z: Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat. 2010; 39(2): 114-123.

Johnson S, MacDonald SF, Cheverie M, et al.: Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. Drug Alcohol Depend. 2012; 124(1-2): 172-176.

Morasco BJ, Turk DC, Donovan DM, et al.: Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013; 127(1-3): 193-199.

Cicero TJ, Lynskey M, Todorov A, et al.: Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008; 139(1): 127-135.

Rice JB, White AG, Birnbaum HG, et al.: A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. Pain Med. 2012; 13(9): 1162-1173.

Rieckmann T, McCarty D, Kovas A, et al.: American Indians with substance use disorders: Treatment needs and comorbid conditions. Am J Drug Alcohol Abuse. 2012; 38(5): 498-504.

Seal KH, Shi Y, Cohen G, et al.: Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012; 307(9): 940-947.

Cohen P, Chen H, Crawford TN, et al.: Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug Alcohol Depend. 2007; 88(suppl 1): S71-S84.

Conroy E, Degenhardt L, Mattick RP, et al.: Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. Child Abuse Negl. 2009; 33(6): 343-352.

Ani C, Bazargan M, Hindman D, et al.: Depression symptomatology and diagnosis: Discordance between patients and physicians in primary care settings. BMC Fam Pract. 2008; 9: 1.

Kroenke K, Spitzer RL, Williams JB, et al.: Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146(5): 317-325.

Hirschfeld RM, Cass AR, Holt DC, et al.: Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005; 18(4): 233-239.

Pergolizzi JV Jr, Gharibo C, Passik S, et al.: Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. 2012; 72(6): 443-451.

Butler SF, Budman SH, Fernandez KC, et al.: Development and validation of the current opioid misuse measure. Pain. 2007; 130(1-2): 144-156.

Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med. 2005; 6(6): 432-442.

Butler SF, Fernandez K, Benoit C, et al.: Validation of the revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.

Compton PA, Wu SM, Schieffer B, et al.: Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008; 36(4): 383-395.

Chou R, Fanciullo GJ, Fine PG, et al.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009; 10(2): 131-146.

Park J, Lavin R: Risk factors associated with opioid medication misuse in community-dwelling older adults with chronic pain. Clin J Pain. 2010; 26(8): 647-655.

Pink LR, Smith AJ, Peng PW, et al.: Intake assessment of problematic use of medications in a chronic noncancer pain clinic. Pain Res Manag. 2012; 17(4): 276-280.

Hariharan J, Lamb GC, Neuner JM: Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007; 22(4): 485-490.

Penko J, Mattson J, Miaskowski C, et al.: Do patients know they are on pain medication agreements? Results from a sample of high-risk patients on chronic opioid therapy. Pain Med. 2012; 13(9): 1174-1180.

Butler SF, Black RA, Cassidy TA, et al.: Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011; 8(1): 29.

Passik SD, Hays L, Eisner N, et al.: Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006; 20(2): 5-13.

Kahan M, Mailis-Gagnon A, Wilson L, et al.: Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 1: General population. Can Fam Physician. 2011; 57(11): 1257-1266, e1407-e1418.

Naliboff BD, Wu SM, Schieffer B, et al.: A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011; 12(2): 288-296.

National Opioid Use Guideline Group: Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain. McMaster University. Available at http://nationalpaincentre.mcmaster.ca/opioid/. Accessed November 21, 2013.

Online opioid calculator. Available at http://opioidcalculatorpracticalpainmanagement.com/. Accessed November 21, 2013.

New York Langone Medical Center: GlobalRPh. Available at http://www.globalrph.com/narcoticonv.htm. Accessed November 21, 2013.

Johns Hopkins Center for Cancer Pain Research opioid conversion program: Available at http://www.hopweb.org/index.cfm?cfid_4634198&cftoken=46515837. Accessed November 21, 2013.

Bohnert AS, Valenstein M, Bair MJ, et al.: Association

between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13): 1315-1321.

Dunn KM, Saunders KW, Rutter CM, et al.: Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152(2): 85-92.

Gomes T, Mamdani MM, Dhalla IA, et al.: Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171(7): 686-691.

Gomes T, Juurlink DN, Dhalla IA, et al.: Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011; 5(1): e13-e22.

Franklin GM, Mai J, Turner J, et al.: Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012; 55(4): 325-331.

Butler SF, Benoit C, Budman SH, et al.: Development and validation of an Opioid Attractiveness Scale: A novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J. 2006; 3: 5.

Romach MK, Schoedel KA, Sellers EM: Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013; 130(1-3): 13-23.

Black R, Coplan P, Cassidy T, et al.: Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinal surveillance network. J Pain. 2012; 13(4S): S58.

Bartholomäus J, Arkenau-Maric E, Galia E: Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012; 9(8): 879-891.

Pfizer Inc, Acura Pharmaceuticals Inc.: Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII [press release]. Available at http://www.pfizer.com/news/press-release/press-release-archive-detail/pfizer_and_acura_announce_fda_approval_of_oxectatm_oxycodone_hcl_usp_cii. Accessed June 26, 2012.

Katz N, Sun S, Johnson F, et al.: ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: Pharmacokinetics, efficacy, and safety. J Pain. 2010; 11(4): 303-311.

Webster LR, Johnson FK, Stauffer J, et al.: Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011; 11(3): 259-275.

Stauffer J, Setnik B, Sokolowska M, et al.: Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced nondependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009; 29(12): 777-790.

thepharmaletter.com: Stability problems see Pfizer recall pain drug Embeda acquired in King deal. Available at http://www.thepharmaletter.com/file/102899/stability-problems-see-pfizer-recall-pain-drug-embeda-acquired-in-kingdeal.html. Accessed November 21, 2013.

Webster LR, Bath B, Medve RA, et al.: Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med. 2012; 13(6): 790-801.

Butler SF, Cassidy TA, Chilcoat H, et al.: Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013; 14(4): 351-358.

Setnik B, Roland CL, Cleveland JM, et al.: The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011; 12(4): 618-631.

Cicero TJ, Ellis MS, Surratt HL: Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012; 367(2): 187-189.

Vosburg SK, Jones JD, Manubay JM, et al.: Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012; 126(1-2): 206-215.

Schoedel KA, Rolleri RL, Faulknor JY, et al.: Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag. 2012; 8(5): 315-327.

Tompkins DA, Lanier RK, Harrison JA, et al.: Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl). 2010; 210(4): 471-480.

Cone EJ, Caplan YH, Black DL, et al.: Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008; 32(8): 530-543.

Robinson-Papp J, Elliott K, Simpson DM, et al.: Problematic prescription opioid use in an HIV-infected cohort: The importance of universal toxicology testing. J Acquir Immune Defic Syndr. 2012; 61(2): 187-193.

Couto JE, Webster L, Romney MC, et al.: Use of an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen. J Clin Pharm Ther. 2011; 36(2): 200-207.

Larson ME, Richards TM: Quantification of a methadone metabolite (EDDP) in urine: Assessment of compliance. Clin Med Res. 2009; 7(4): 134-141.

Manchikanti L, Malla Y, Wargo BW, et al.: Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. Pain Physician. 2011; 14(2): 175-187.

Starrels JL, Becker WC, Alford DP, et al.: Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010; 152(11): 712-720.

Starrels JL, Fox AD, Kunins HV, et al.: They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012; 27(11): 1521-1527.

Peppin JF, Passik SD, Couto JE, et al.: Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012; 13(7): 886-896.

United States General Accounting Office: State monitoring programs may help to reduce illegal diversion. Available at http://www.gao.gov/products/GAO-04-524T. Accessed November 21, 2013.

Green TC, Mann MR, Bowman SE, et al.: How does use of a prescription monitoring program change medical practice? Pain Med. 2012; 13(10): 1314-1323.

Reifler LM, Droz D, Bailey JE, et al.: Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3): 434-442.

Lum PJ, Little S, Botsko M, et al.: Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011; 56(suppl 1): S91-S97.

Argoff CE, Wilson L, Kahan MM: Managing aberrant drug behavior in primary care. Paper presented at the International Conference on Opioids, Boston, MA, June 10-14, 2012.

Meghani SH, Wiedemer NL, Becker WC, et al.: Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med. 2009; 10(5): 858-865.

Peng P, Tumber P, Stafford M, et al.: Experience of methadone therapy in 100 consecutive chronic pain patients in a multidisciplinary pain center. Pain Med. 2008; 9(7): 786-794.

Mattick RP, Breen C, Kimber J, et al.: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; (3): CD002209.

Shields LB, Hunsaker Iii JC, Corey TS, et al.: Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007; 52(6): 1389-1395.

Jones JD, Sullivan MA, Manubay J, et al.: The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology. 2011; 36(2): 411-422.

Blondell RD, Ashrafioun L, Dambra CM, et al.: A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med. 2010; 4(3): 140-146.

Comer SD, Sullivan MA, Vosburg SK, et al.: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105(4): 709-718.

Alho H, Sinclair D, Vuori E, et al.: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007; 88(1): 75-78.

Cicero TJ, Surratt HL, Inciardi J: Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007; 3(6): 302-308.

Fiellin DA, Weiss L, Botsko M, et al.: Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011; 56(suppl 1): S33-S38.

Gowing L, Ali R, White JM: Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009; (3): CD002025.

Peppin JF, Coleman JJ, Kirsh KL: Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med. 2011; 27(2): 91-119.

Nicholson SC, Evanyo K, Salinas GD, et al: Extended-release/ long-acting opioid REMS may fill the need for prescribers’ appropriate use education. J Opioid Manag. 2012; 8(4): 212-216.

Slevin KA, Ashburn MA: Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011; 7(2): 109-115.

Kuroyanagi T, Ishii M: Declaration of Helsinki Expert Conference on the Ethics of Placebo Control in Clinical Trials - comments on the "reasonable availability" approach. Japanese Medical Association Journal. 2011; 54(6): 346-350.